Effectiveness and Safety of Vibegron in Patients with Overactive Bladder: A Retrospective Chart Review of Patient Outcomes

Effectiveness and Safety of Vibegron in Patients with Overactive Bladder: A Retrospective Chart Review of Patient Outcomes - Effectiveness and Safety of Vibegron in Patients with Overactive Bladder: A Retrospective Chart Review of Patient Outcomes

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000037233

Enrollment

100

Registered

2019-07-02

Start date

2019-07-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

overactive bladder

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients over 20 years who met the all following criteria; 1) Patients who treated with vibegron over 4 weeks for OAB during November, 2018 to June, 2019. 2) Patients who collected OABSS at the start of vibegron and 4 weeks later.

Exclusion criteria

Exclusion criteria: Nothing

Design outcomes

Primary

Measure	Time frame
The change in Overactive Bladder Symptom Score (OABSS) total score from baseline to 4 weeks	—

Secondary

Measure	Time frame
1) Change in OABSS sub-scores (4 elements) from baseline 2) Change in International Prostate Symptom Score (IPSS) total score from baseline 3) Change in IPSS sub-scores (3 and 7 elements) from baseline 4) Change in IPSS-QOL score from baseline 5) Proportion of subjects with minimum changes in OABSS total score 6) Individual scores of King's Health Questionnaire (KHQ) 7) Subgroup analyses for OABSS, IPSS, IPSS-QOL, and KHQ	—

Measure

Time frame

1) Change in OABSS sub-scores (4 elements) from baseline 2) Change in International Prostate Symptom Score (IPSS) total score from baseline 3) Change in IPSS sub-scores (3 and 7 elements) from baseline 4) Change in IPSS-QOL score from baseline 5) Proportion of subjects with minimum changes in OABSS total score 6) Individual scores of King's Health Questionnaire (KHQ) 7) Subgroup analyses for OABSS, IPSS, IPSS-QOL, and KHQ

—

Countries

Japan

Contacts

Public ContactRirei Araiya

Mebix, Inc. Clinical Research Division

vibegron-retro@mebix.co.jp03-4362-4504

Outcome results